About us

      François   Espanola   العربية   Hindi    中國  Thai             

 

 

 Home   About us   Patents   Vaccines Diagnostics Research  Clinical Trials Facilities   Investment  Global Health   Contact us 

 

Global Health Partners

The Fastest Growing Company in America

 

JN Membership with  Global Organizations

 

Clinton Global Health (NY)

GBC (New York - S. Africa)

Global Health Council (DC)

AID+TRADE (UK)

 

 

 

 

 

 

 

 

 

"Vaccination to prevent millions of deaths per year, and yet millions more are dying due to the lack of vaccines. Stringent regulatory hurdles and the perception of moderate returns on investment have not encouraged companies like us to enter the markets faster."

"Prevention if better then cure —innovation of new vaccines and diagnostics for healthcare make a real difference for the world. To realize this goal, we recognize that JN resources and capabilities are necessary, but not sufficient—we just can’t do it alone. Successful, productive partnerships are essential for JN’s ongoing pursuit of innovation and excellence."

Jeeri R. Reddy, M.S., Ph.D.
Scientific Director / CEO


 

 

"The supply of vaccines, be it in response to a pandemic or seasonal outbreaks in Africa, requires robust production processes supported by manufacturers with stringent supply chain routines and quality systems who are able to react quickly to the demand. With vaccine candidates, improved processes and increased capacity, vaccine manufacturers are better prepared, but there is still some way to go to meet the goals of JN operations in West Africa."

Noel Koumae. M.D.
Medical Director and Chief Operational Officer Africa


The Founder of Corporation

 JN-International Medical Corporation is a privately held Nebraska Corporation stated by an entrepreneur in a rural Nebraska town in 1998. The founder, while researching for vaccines during 1995, he founded his own research by trading rapid diagnostics in international market. In a decade's time, his dreams came to realities and established a track record of delivering on the promise of healthcare products to international community. Today, JN is among the world's leading biotech companies, with innovated vaccines and diagnostic products for detection and prevention of infectious diseases. JN has focused its energies and based its success in 10 straight years in development of innovative vaccines and diagnostics, sound business strategy, and a passion for people around the world, who receive our products. JN became one of the world’s leading biotechnology companies practicing world class medicine with our groundbreaking scientific discoveries, bringing to market with Innovative Vaccines and Diagnostics and proved the commercial viability of this new technology through recognition of our forward-thinking.

Our Mission

Our mission is to be the leading biotechnology company, using genetic engineering technology to discover, develop, and commercialize diagnostics that address significant medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of international communities, and to seeking significant returns, based on the continual pursuit of scientific and operational excellence. JN believes that this goal can be achieved by means of our product superiority, affordability and accessibility. Our organization has already achieved vaccine marketing success through a decade of unique as well as innovative research and technology combined with an innovative marketing strategy.

Company Profile

 JN-International development pipeline has never been more robust and promising, with the projects below under way, JN pipeline vaccines are composed of potential vaccines against Infectious, Sexually transmitted diseases and Stroke. JN's clinical trials are crucial to the exploration of new vaccines for developing countries that may address significant unmet disease prevention. JN's development pipeline continues to grow, now numbering over 4 vaccine projects. The pipeline is also balanced between breakthrough innovations and new indications for existing, well-understood products that may prevent from common diseases and disorders. Company profile with GBC: TB    Malaria

What do other people say about our company?

The company’s emphasis on strong basic research combined with an applied focus on unequivocal medical needs has been instrumental to our success and growth. Our company received recognition from the world most popular NGO's, International Health Organizations, and Ministry of Health.

 

JN/GBC Contribution on Prevention of Malaria in Zambia

 

COUNTY AND REGIONAL OFFICES 

UNITED STATES OF AMERICA

6912 North 97th Circle, Omaha

Nebraska 68122

Tel. 402-884-3477; Fax. 402-614-4437

E-Mail:  drreddy@jn-vaccines.org

 

IVORY COAST

27 BP 71 ABIDJAN

 Tel / Fax. 225.22.42.87.93

E-Mail:  drnoel@jn-vaccines.org

 

 

 

MALAYSIA

No 23  Suite 5 ,1st Floor

Subang Jaya, Kuala Lumpur  

Tel. 601933886911  

E-Mail:  param@jn-vaccines.org

 

 

 

Disclaimer
Copyright © 1998 JN-International, Inc., USA.

Accessing JN's web pages or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.